title: Individual dosing of ASA prophylaxis by controlling platelet aggregation.
abstract: Acetylsalicylic acid is widely used in the primary and secondary prevention of cardiovascular diseases. In the current study, we used platelet aggregation ex vivo in platelet-rich plasma induced with arachidonic acid as a routine method for the determination of the individual dose of acetylsalicylic acid necessary to inhibit platelet aggregation in 108 patients with cardiovascular diseases. In 40% of all patients studied, a dose of 30 mg/day was sufficient to block the arachidonic acid-induced platelet aggregation nearly completely. In 50% of all patients, a dose of 100 mg/day was necessary. In 10% of all patients, the dose had to be further increased to 300 mg/day or even to 500 mg/day to inhibit platelet aggregation nearly completely. These results demonstrate that platelet aggregation can be used as a simple routine laboratory method to control acetylsalicylic acid treatment in patients with cardiovascular diseases and to determine individual doses of acetylsalicylic acid for a nearly complete inhibition of platelet aggregation. With a standard dose of 100 mg/day, 10% of the patients were nonresponders.
authors.affiliation: Department of Internal Medicine, District Hospital of Stadtroda/Thuringia, Germany. helgeredlich@t-online.de
authors.forename: G
authors.initials: G
authors.lastname: Syrbe
authors.forename: H
authors.initials: H
authors.lastname: Redlich
authors.forename: B
authors.initials: B
authors.lastname: Weidlich
authors.forename: J
authors.initials: J
authors.lastname: Ludwig
authors.forename: S
authors.initials: S
authors.lastname: Kopitzsch
authors.forename: A
authors.initials: A
authors.lastname: Göckefitz
authors.forename: T
authors.initials: T
authors.lastname: Herzog
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016718:Arachidonic Acid / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D010979:Platelet Function Tests; D019851:Thrombophilia / Q000097:blood / Q000150:complications / Q000188:drug therapy*
chemical_list: D010975:Platelet Aggregation Inhibitors; D016718:Arachidonic Acid; D001241:Aspirin